Missed ASGCT? No worries!

BOOTH #1137 | New Orleans, LA

Let’s book a meeting and see how Viralgen’s strengths can help you conquer your next project: 

text (2)

Forecast your serotype’s performance from our 1,500+ AAV runs

Group 2

Leverage Pro10™, our AAV platofrm designed for best-in-class speed to scale

text (1)

Partner with our team of experts that has 100% success rate in IND/IMPD dossier submissions

Schedule A Meeting

Fresh research on AAV manufacturing

Missed Poster Hall I2 or booth #1137 at ASGCT? Get the scoop on the latest research from the scientific and technology leads at Viralgen, who are helping shape the future of AAV-based gene therapy manufacturing.

Download the posters below to catch up.

Poster_ASGCT 2025_Viralgen_Sonia Stinus_final

Benefits of High-Throughput Sequencing-Based Methods for In-Depth Characterization of Recombinant AAV Products
Presented by Sonia Stinus, PhD.
Poster # AMA905

Integrating Raman Spectroscopy and Genome-Scale Modeling

Integrating Raman Spectroscopy and Genome-Scale Modeling to Enhance AAV Upstream Manufacturing
Presented by Itsasne Arangoa.
Poster # AMA1539

ASGCT2025_Poster_Enhancing_USP_Performance_Ainara_Apezteguia

Enhancing the Upstream Performance of Adeno-Associated Virus (AAV) Vector Manufacturing via Multivariate Data Analysis
Presented by Ainara Apezteguia.
Poster # AMA1624

Leveraging Historical Data and Percentile based Modeling FINAL

Leveraging Historical Data and Percentile based Modeling for Improved AAV Production Scaling
Presented by Itsasne Arangoa.
Poster # AMA1546

Streamlining Advanced Therapy Medicinal Product Manufacturing: A Platform Approach for Accelerating Gene Therapy Commercialization at Viralgen

Streamlining Advanced Therapy Medicinal Product Manufacturing: A Platform Approach for Accelerating Gene Therapy Commercialization at Viralgen
Presented by Cesar Trigueros, PhD.
Poster # AMA988

UPCOMING WEBINAR

Exploring key regulatory considerations to ensure patient safety in the gene therapy space

Tuesday, July 1st 2025, 11:00am EST

With Featured Panelist by María Orío, Director of Regulatory Affairs, Viralgen

Please review the following rules: